Invasive Lung Cancer Surgery Linked to Long-Term Opioid Use

A new study has demonstrated that patients undergoing more invasive surgery for early stage non-small cell lung cancer (NSCLC) are more likely to become chronic opioid users than patients who undergo minimally invasive surgery for the same condition. Surgery for early-stage lung cancer often results in persistent pain, which can be debilitatingly intense for approximately 10% of patients. It is considered standard of care to prescribe opioids immediately after surgery with the intention of contr...
Continue reading

ROS1+ Non-Small Cell Lung Cancer: Entrectinib Shows Promise

Results have been strong for phase 1 and 2 clinical trials of entrectinib (RXDX-101), an orally available selective tyrosine kinase inhibitor, in treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). A ROS1 rearrangement is a chromosomal abnormality where ROS1 has mutated so that it signals cells to continuously survive and multiply, thereby causing cancer. ROS1-positive NSCLC is a distinct molecular subset of NSCLC that occurs in 1% to 2% of lung cancer cases. Compared wi...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.